Get Newsletter
Alzheimer Research Forum - Networking for a Cure Alzheimer Research Forum - Networking for a CureAlzheimer Research Forum - Networking for a Cure
  
What's New HomeContact UsHow to CiteGet NewsletterBecome a MemberLogin          
Papers of the Week
Current Papers
ARF Recommends
Milestone Papers
Search All Papers
Search Comments
News
Research News
Drug News
Conference News
Research
AD Hypotheses
  AlzSWAN
  Current Hypotheses
  Hypothesis Factory
Forums
  Live Discussions
  Virtual Conferences
  Interviews
Enabling Technologies
  Workshops
  Research Tools
Compendia
  AlzGene
  AlzRisk
  Antibodies
  Biomarkers
  Mutations
  Protocols
  Research Models
  Video Gallery
Resources
  Bulletin Boards
  Conference Calendar
  Grants
  Jobs
Early-Onset Familial AD
Overview
Diagnosis/Genetics
Research
News
Profiles
Clinics
Drug Development
Companies
Tutorial
Drugs in Clinical Trials
Disease Management
About Alzheimer's
  FAQs
Diagnosis
  Clinical Guidelines
  Tests
  Brain Banks
Treatment
  Drugs and Therapies
Caregiving
  Patient Care
  Support Directory
  AD Experiences
Community
Member Directory
Researcher Profiles
Institutes and Labs
About the Site
Mission
ARF Team
ARF Awards
Advisory Board
Sponsors
Partnerships
Fan Mail
Support Us
Return to Top
Home: Papers of the Week
Annotation


Kang DE, Yoon IS, Repetto E, Busse T, Yermian N, Ie L, Koo EH. Presenilins mediate phosphatidylinositol 3-kinase/AKT and ERK activation via select signaling receptors. Selectivity of PS2 in platelet-derived growth factor signaling. J Biol Chem. 2005 Sep 9;280(36):31537-47. PubMed Abstract

  
Comments on Paper and Primary News
  Comment by:  Tommaso Russo, ARF Advisor
Submitted 22 July 2005  |  Permalink Posted 22 July 2005
  I recommend this paper

  Primary News: Presenilins Work Overtime to Control Akt, Tau, and Aβ—n-3 Fatty Acids Aid and Abet

Comment by:  Frederic Calon, Gregory Cole, ARF Advisor, Sally A. Frautschy
Submitted 25 July 2005  |  Permalink Posted 25 July 2005

This report from Akbar and Kim adds to their earlier work in this area by providing compelling evidence for an impact of DHA on enhancing the rate of PI3K>Akt signaling in neurons and brain by increasing phosphatidylserine (PS) and translocation-dependent activation of Akt through its pleckstrin homology domain. Because of the well-established importance of Akt in "survival signaling" in multiple neurotrophic factor pathways, the paper establishes the significance of maintaining adequate CNS DHA levels in neurodegenerative diseases, including Alzheimer disease (AD). Average DHA intake in the USA is clearly deficient and on the order of 60-80 mg per day in contrast to expert panel recommendations in the range of 200-300 mg per day, and multiple studies have associated increased Alzheimer risk with reduced fish or omega-3 fatty acid intake and reduced DHA blood levels (MacLean, 2005). Part of the beauty of DHA's Akt enhancement mechanism shown by Akbar and Kim is that it should enhance the neuroprotective activity of appropriately presented neurotrophic factors rather than flood...  Read more

  Primary News: Presenilins Work Overtime to Control Akt, Tau, and Aβ—n-3 Fatty Acids Aid and Abet

Comment by:  Othman Ghribi
Submitted 25 July 2005  |  Permalink Posted 25 July 2005

Kang and co-workers examined the effect of PS1 and PS2 deficiency on PI3/Akt and ERK pathways, highlighting the importance of upstream cell-surface receptors in PS1- and PS2-mediated Akt and ERK signaling. The authors demonstrate that the loss of PS1 and PS2 inhibits the PI3/Akt pathway, increasing tau phosphorylation via GSK-3 activation and suppressing the ERK pathway. Although GSK-3 activation, regulated by PI3/Akt signaling (or by Wnt/β-catenin pathways), is viewed as the main player in the phosphorylation of tau, ERK dysregulation is also likely to play an important role in the increased phosphorylation of tau protein (Perry et al., 1999; Roder et al., 1993). In addition to the phosphorylation of tau, the PI3/Akt and ERK pathways play key roles in the survival of neurons and synaptic plasticity, which collectively are involved in the pathophysiology of a variety of neurodegenerative disorders, in particular Alzheimer disease and tauopathy. This paper complements the two recent papers by Saura et al. (2004) and Feng et al. (2004) in showing that the loss of both PS1 and PS2...  Read more

  Primary News: Presenilins Work Overtime to Control Akt, Tau, and Aβ—n-3 Fatty Acids Aid and Abet

Comment by:  Carlos A. Saura
Submitted 26 July 2005  |  Permalink Posted 26 July 2005

Kang and colleagues described a new role of presenilins on the highly conserved ERK signaling cascade. Specifically, these authors demonstrate that loss of presenilins alters the expression, degradation, and function of the tyrosine kinase receptor PDGF, which results in dysregulation of the ERK1/2 signaling pathway. Interestingly, the regulation of PDGF receptor is mediated by the NTF of PS2 through its interaction with the transcription factor FHL2. Unlike PDGF signaling, altered serum-induced Akt/ERK activation in PS-/- cells is reconstituted by expression of PS1 or PS2. This indicates that under normal conditions presenilins regulate directly or indirectly the Akt and ERK signaling pathways by affecting still unknown cell surface receptors or signaling molecules. While these results open an interesting avenue for future investigations, it will be important to dissect the physiological relevance of these findings in cellular events regulated by normal and mutant presenilins such as cell proliferation and survival.

Familial forms of Alzheimer´s and frontotemporal...  Read more


  Primary News: Presenilins Work Overtime to Control Akt, Tau, and Aβ—n-3 Fatty Acids Aid and Abet

Comment by:  Donna McPhie
Submitted 27 July 2005  |  Permalink Posted 29 July 2005
  I recommend this paper

In their highly interesting paper, Kang and colleagues demonstrate an important additional role for the presenilins independent of their role in γ-secretase activity. This role is one of modulating several signal transduction pathways by influencing upstream receptors in the pathways. They further characterize presenilin’s role in the PI3 kinase/Akt pathway and its link to tau phosphorylation. A specific novel function for PS2 in the modulation of the MEK/ERK pathway is also demonstrated. This is shown to happen by a direct effect of PS2 on the PDGF receptor. This is an exciting finding that potentially directly links the presenilins to pathways shown to be important in learning and memory.

View all comments by Donna McPhie

  Primary News: Presenilins Work Overtime to Control Akt, Tau, and Aβ—n-3 Fatty Acids Aid and Abet

Comment by:  Nikolaos K. Robakis
Submitted 3 August 2005  |  Permalink Posted 3 August 2005

The paper by Kang et al. is very interesting, both because it confirms the important role presenilins play in the activation of the PI3K/Akt pathway, and because it describes a novel role of PS2 in PDGF signaling. More important, for the mechanism involved in the induction of AD by FAD mutations, this paper supports the hypothesis by Baki et al.) that presenilins may prevent AD pathology, including tau hyperphosphorylation, by activating the PI3K/Akt pathway, while presenilin FAD mutations may promote AD pathology by inhibiting this pathway. Interestingly, the paper confirms evidence that these novel presenilin functions are independent of γ-secretase activity (Baki et al., 2004). It is known that absence of PS1 or presence of PS1 mutations promotes apoptotic changes including activation of caspase-3, and that these changes depend on the cadherin/PS1/PI3K/Akt/GSK-3 pathway. It is not unreasonable to hypothesize that these apoptotic changes, triggered by presenilin FAD mutations, may...  Read more
  Submit a Comment on this Paper
Cast your vote and/or make a comment on this paper. 

If you already are a member, please login.
Not sure if you are a member? Search our member database.

*First Name  
*Last Name  
Country or Territory:
*Login Email Address  
*Password    Minimum of 8 characters
*Confirm Password  
Stay signed in?  

I recommend this paper

Comment:

(If coauthors exist for this comment, please enter their names and email addresses at the end of the comment.)

References:


*Enter the verification code you see in the picture below:


This helps Alzforum prevent automated registrations.

Terms and Conditions of Use:Printable Version

By clicking on the 'I accept' below, you are agreeing to the Terms and Conditions of Use above.
 
 

REAGENTS/MATERIAL:

The following antibodies were used in this study: monoclonal antibody PSN2 (against residues 31–56 of human PS1) and polyclonal APP antibody CT15 (against C-terminal 15 residues of APP). Monoclonal anti-phosphotyrosine (Zymed Laboratories Inc.), phospho-ERK1/2 (Cell Signaling), and FHL2 (MBL) were obtained from commercial sources. Monoclonal antibodies against tau, PHF1 (Peter Davies), Tau-1 (Gloria Lee), and Tau46 (Gloria Lee) were generous gifts. Polyclonal antibody against phospho-202 tau was purchased from BIOSOURCE. Polyclonal antibodies against phospho-GSK3/a/b, phospho-Akt, Akt, ERK1/2, PDGFRb, IGF1-R, PS2 CTF, and phospho-33/37/41 b-catenin were purchased from Cell Signaling. Polyclonal anti-PS2 N-terminal fragment (NTF) antibody was purchased from the Calbiochem.

Print this page
Email this page
Alzforum News
Papers of the Week
Text size
Share & Bookmark
Desperately

Antibodies
Cell Lines
Collaborators
Papers
Research Participants
Copyright © 1996-2013 Alzheimer Research Forum Terms of Use How to Cite Privacy Policy Disclaimer Disclosure Copyright
wma logoadadad